Increased virulence of zygomycetes organisms following exposure to voriconazole: a study involving fly and murine models of zygomycosis

Journal of Infectious Diseases

Volumn 199, Issue 9, 2009, Pages 1399-1406

  Lamaris, Gregory A ^a,c   Ben Ami, Ronen ^a   Lewis, Russell E ^a,b   Chamilos, Georgios ^a   Samonis, George ^c   Kontoyiannis, Dimitrios P ^a,b,d  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b UNIVERSITY OF HOUSTON   (United States)

^c UNIVERSITY HOSPITAL OF HERAKLION   (Greece)

^d UNIVERSITY OF TEXAS MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B; CASPOFUNGIN; ITRACONAZOLE; VORICONAZOLE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ASPERGILLUS FUMIGATUS; CONTROLLED STUDY; DROSOPHILA; FEMALE; FUNGAL STRAIN; FUNGAL VIRULENCE; GENE EXPRESSION; HISTOPATHOLOGY; LUNG INFECTION; MOUSE; MUCORMYCOSIS; NONHUMAN; PNEUMONIA; PRIORITY JOURNAL; RHIZOPUS ORYZAE; STRESS; SURVIVAL RATE; TISSUE REPAIR; ZYGOMYCETES;

AMPHOTERICIN B; ANIMALS; ANTIFUNGAL AGENTS; ASPERGILLUS FUMIGATUS; DISEASE MODELS, ANIMAL; DROSOPHILA; FUNGI; HUMANS; ITRACONAZOLE; MICE; MUCOR; PYRIMIDINES; RHIZOPUS; TRIAZOLES; VIRULENCE; ZYGOMYCOSIS;

EID: 65649120359     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/597615     Document Type: Article

References (19)

1. Roden MM, Zaoutis TE, Buchanan WL, et al. Epidemiology and outcome of zygomycosis: a review of 929 reported cases. Clin Infect Dis 2005; 41:634-53.
2. Siwek GT, Dodgson KJ, de Magalhaes-Silverman M, et al. Invasive zygomycosis in hematopoietic stem cell transplant recipients receiving voriconazole prophylaxis. Clin Infect Dis 2004; 39:584-7.
3. Dannaoui E, Meletiadis J, Mouton JW, Meis JF, Verweij PE. In vitro susceptibilities of Zygomycetes to conventional and new antifungals. J Antimicrob Chemother 2003; 51:45-52.
4. Imhof A, Balajee SA, Fredricks DN, Englund JA, Marr KA. Breakthrough fungal infections in stem cell transplant recipients receiving voriconazole. Clin Infect Dis 2004; 39:743-6.
5. Kontoyiannis DP, Lionakis MS, Lewis RE, et al. Zygomycosis in a tertiary-care cancer center in the era of Aspergillus-active antifungal therapy: a case-control observational study of 27 recent cases. J Infect Dis 2005; 191:1350-60.
6. Kontoyiannis DP, Wessel VC, Bodey GP, Rolston KV. Zygomycosis in the 1990s in a tertiary-care cancer center. Clin Infect Dis 2000; 30:851-6.
7. Trifilio S, Singhal S, Williams S, et al. Breakthrough fungal infections after allogeneic hematopoietic stem cell transplantation in patients on prophylactic voriconazole. Bone Marrow Transplant 2007; 40:451-6.
8. Marty FM, Cosimi LA, Baden LR. Breakthrough zygomycosis after voriconazole treatment in recipients of hematopoietic stem-cell transplants. N Engl J Med 2004; 350:950-2.
9. Kontoyiannis DP, Lewis RE. Invasive zygomycosis: update on pathogenesis, clinical manifestations, and management. Infect Dis Clin NorthAm 2006; 20:581-607, vi.
10. Chamilos G, Lewis RE, Kontoyiannis DP. Lovastatin has significant activity against Zygomycetes and interacts synergistically with voriconazole. Antimicrob Agents Chemother 2006; 50:96-103.
11. LionakisMS,Lewis RE,MayGS, et al. Toll-deficient Drosophila flies as a fast, high-throughput model for the study of antifungal drug efficacy against invasive aspergillosis and Aspergillus virulence. J Infect Dis 2005; 191: 1188-95.
12. Chamilos G, Lionakis MS, Lewis RE, et al. Drosophila melanogaster as a facile model for large-scale studies of virulence mechanisms and antifungal drug efficacy in Candida species. J Infect Dis 2006; 193:1014-22.
13. Chamilos G, Lewis RE, Hu J, et al. Drosophila melanogaster as a model host to dissect the immunopathogenesis of zygomycosis. Proc Natl Acad Sci U S A 2008; 105:9367-72.
14. Lewis RE, Prince RA, Chi J, Kontoyiannis DP. Itraconazole preexposure attenuates the efficacy of subsequent amphotericin B therapy in a murine model of acute invasive pulmonary aspergillosis. Antimicrob Agents Chemother 2002; 46:3208-14.
15. Ibrahim AS, Bowman JC, Avanessian V, et al. Caspofungin inhibits Rhizopus oryzae 1,3-D-glucan synthase, lowers burden in brain measured by quantitative PCR, and improves survival at a low but not a high dose during murine disseminated zygomycosis. Antimicrob Agents Chemother 2005; 49:721-7.
16. Chamilos G, Lionakis MS, Lewis RE, Kontoyiannis DP. Role of minihost models in the study of medically important fungi. Lancet Infect Dis 2007; 7:42-55.
17. Antachopoulos C, Meletiadis J, Roilides E, Sein T, Walsh TJ. Rapid susceptibility testing of medically important zygomycetes by XTT assay. J Clin Microbiol 2006; 44:553-60.
18. Stroschein-Stevenson SL, Foley E, O'Farrell PH, Johnson AD. Identification of Drosophila gene products required for phagocytosis of Candida albicans. PLoS Biol 2006; 4:e4.
19. Wu T, Wright K, Hurst SF, Morrison CJ. Enhanced extracellular production of aspartyl proteinase, a virulence factor, by Candida albicans isolates following growth in subinhibitory concentrations of fluconazole. Antimicrob Agents Chemother 2000; 44:1200-8.